Comparative Efficacy of Magnesium Supplement and Melatonin Congener in Young Adults With Primary Insomnia

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06996171

Enrollment

Registered

2025-05-30

Start date

2025-05-05

Completion date

2025-10-30

Last updated

2025-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Insomnia

Keywords

Primary Insomnia, Magnesium supplement, Melatonin congener

Brief summary

Sleep is essential for our overall health and well-being, much like food and water. It plays a vital role in numerous bodily functions. Many studies have been conducted to determine the efficacy of melatonin congeners and Mg supplements in patients with insomnia separately. This study aims to compare the efficacy of melatonin and magnesium supplements in young adults with primary insomnia. Most insomnia studies focus on older adults or individuals with comorbidities. Targeting otherwise healthy young adults brings age-specific relevance and novel insight.

Interventions

DRUGMagnesium glycinate

Tab Magnesium glycinate 500mg will be given to one group for treatment of primary insomnia

DRUGMelatonin

Tab Melatonin 10mg will be given to the other group for treatment of primary insomnia

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Age 18-40 years * Gender: Male and Females (Non-pregnant & Non lactating) * Diagnosed cases of primary insomnia according to following criteria: * Difficulty falling asleep, staying asleep or nonrestorative sleep * This difficulty is present despite adequate opportunity & circumstance to sleep * This impairment in sleep is associated with daytime impairment or distress * This sleep difficulty occurs at least 3 times per week and has been a problem for at least 1 month

Exclusion criteria

* Insomnia due to a known underlying cause * Any psychiatric illness * Active use of sedative hypnotics

Design outcomes

Primary

Measure	Time frame	Description
Insomnia Severity Index (ISI)	4 weeks	ISI is a 7-item questionnaire used to determine the severity of insomnia.

Countries

Pakistan

Contacts

Primary ContactMushayada Irshad, MBBS, MPhil Pharmacology

mishy2360@gmail.com+923237088421

Backup ContactUsman Nawaz, MBBS, MPhil, PhD Pharmacology

drusmannawaz@gmail.com+923335641664

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026